Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk in drug trials.
Sugarman J, Levine C. Sugarman J, et al. Lancet. 2006 Dec 23;368(9554):2205. doi: 10.1016/S0140-6736(06)69881-4. Lancet. 2006. PMID: 17189020 No abstract available.
"Special scrutiny": a targeted form of research protocol review.
Levine C, Faden R, Grady C, Hammerschmidt D, Eckenwiler L, Sugarman J; Consortium to Examine Clinical Research Ethics. Levine C, et al. Among authors: sugarman j. Ann Intern Med. 2004 Feb 3;140(3):220-3. doi: 10.7326/0003-4819-140-3-200402030-00013. Ann Intern Med. 2004. PMID: 14757620
Dealing with the long-term social implications of research.
Fleischman A, Levine C, Eckenwiler L, Grady C, Hammerschmidt DE, Sugarman J. Fleischman A, et al. Among authors: sugarman j. Am J Bioeth. 2011 May;11(5):5-9. doi: 10.1080/15265161.2011.568576. Am J Bioeth. 2011. PMID: 21534138 Free PMC article.
Applying justice in clinical trials for diverse populations.
Tilburt J, Ford JG, Howerton MW, Gary TL, Lai GY, Bolen S, Baffi C, Wilson RF, Tanpitukpongse TP, Powe NR, Bass EB, Sugarman J. Tilburt J, et al. Among authors: sugarman j. Clin Trials. 2007;4(3):264-9. doi: 10.1177/1740774507079440. Clin Trials. 2007. PMID: 17715253
Addressing guideline and policy changes during pragmatic clinical trials.
Curtis LH, Dember LM, Vazquez MA, Murray D, DeBar L, Staman KL, Septimus E, Mor V, Volandes A, Wells BL, Huang SS, Green BB, Coronado G, Meyers CM, Tuzzio L, Hernandez AF, Sugarman J. Curtis LH, et al. Among authors: sugarman j. Clin Trials. 2019 Aug;16(4):431-437. doi: 10.1177/1740774519845682. Epub 2019 May 14. Clin Trials. 2019. PMID: 31084378 Free PMC article.
An ethics framework for consolidating and prioritizing COVID-19 clinical trials.
Meyer MN, Gelinas L, Bierer BE, Hull SC, Joffe S, Magnus D, Mohapatra S, Sharp RR, Spector-Bagdady K, Sugarman J, Wilfond BS, Lynch HF. Meyer MN, et al. Among authors: sugarman j. Clin Trials. 2021 Apr;18(2):226-233. doi: 10.1177/1740774520988669. Epub 2021 Feb 2. Clin Trials. 2021. PMID: 33530721 Free PMC article.
595 results